This book focuses on understanding biomimetic architecture and its role as a sustainable design tool. It presents the role of biomimicry in mitigation and adaptation to climate change and examines how biomimetic architecture can provide healthy solutions to limit the spread of COVID-19 in buildings and cities. Coverage includes global examples of biomimetic approaches and buildings, an evaluation of the performance of biomimicry applications in architecture to illustrate best practices, and an exploration of how nature can offer inspiration in building design to conserve resources and save energy use as well as curb carbon emissions – a reaffirmed goal of COP 26 and an outcome of Glasgow Climate Pact. Finally, the book presents guidelines to enhance urban areas and healthier spaces in buildings to meet COVID-19 social distance regulations and beyond.

Examines global applications of biomimicry in architecture;
Highlights the importance of biomimicry in driving livability in cities and buildings;
Explores the role of biomimetic architecture in mitigating climate change.
“The line of argument developed is highly relevant to the present, in addition to being original and pertinent to research on urban regeneration, especially in regard to the exploration of the use of biomimicry architecture in response to changing urban demands.”

—Alessandra Battisti, Ph.D., Professor of Architecture, University of Rome La Sapienza-

Blockchain, a most common synonym for distributed ledger (Tschorsch and Scheuermann in IEEE Commun Surv Tutor 18:2084–2123, 2016), is an emerging platform. Blockchain is used to support transactional services within a multi-party business network. The aim is to enable a significant reduction in cost and risk for all involved parties through the creation of novel and enhanced business models. Data maintained within the distributed ledger can only be accessed through the execution of a smart contract (Seijas, Scripting smart contracts for distributed ledger technology, International Association for Cryptologic Research, 1156, 2016) that governs a transaction with rules. The core driving idea for designing the architecture of a blockchain platform is to guarantee that no single business party can append, modify or delete any record residing within the ledger without going through the necessary consensus from other business parties within the network. This empowers the system and ensures the data is immutable. Examples of such data include but are not limited to legal and financial trails. Given the aforementioned important features, blockchain technology is a revolutionary trending technology with the ability to offer tremendous disrupting changes to different industries. Gartner’s 2016 research report (Gartner, Gartner’s 2016 hype cycle for emerging technologies special report, 2016) identified blockchain as one of the key platform-enabling technologies to track. While there is currently a lack of widely identified and accepted standards for blockchain technology, there is a rising agreement that blockchain is currently entering its height of extravagant expectations. The report anticipated that it would take 5 to 10 years for blockchain technology to be easily and widely adopted. Nowadays, almost five years later most blockchain efforts, especially the ones applied to business environments, are still in the early stages not reaching the widely adoption stage also not realizing a widely accepted standard so far. In this book chapter, an attempt will be made to cover the main concepts of blockchain, its underlying technologies, Smart Contracts, and Decentralized Applications (DApps).

BMI-1 is an essential regulator of transcriptional silencing during development. Recently, the role of BMI-1 in the DNA damage response has gained much attention, but the exact mechanism of how BMI-1 participates in the process is unclear. Here, we establish a role for BMI-1 in the repair of DNA double-strand breaks by homologous recombination (HR), where it promotes DNA end resection. Mechanistically, BMI-1 mediates DNA end resection by facilitating the recruitment of CtIP, thus allowing RPA and RAD51 accumulation at DNA damage sites. Interestingly, treatment with transcription inhibitors rescues the DNA end resection defects of BMI-1-depleted cells, suggesting BMI-1-dependent transcriptional silencing mediates DNA end resection. Moreover, we find that H2A ubiquitylation at K119 (H2AK119ub) promotes end resection. Taken together, our results identify BMI-1-mediated transcriptional silencing and promotion of H2AK119ub deposition as essential regulators of DNA end resection and thus the progression of HR.

Liver transplantation (LT) is the definitive treatment of end-stage liver disease. The long-term survival following LT spurred more interest in improving the quality of life of patients. This was a cohort study that included 23 pediatric liver transplant recipients who underwent LT due to hereditary or metabolic liver diseases. Bone health assessment was performed at their last follow up clinically (anthropometric measures), biochemically and radiologically (Dual Energy X-ray Absorptiometry [DEXA] scans). Poor bone health was defined as z-score <-1. Mean age at LT was 5.77 years (standard deviation [SD] 3.64) and 43% were males. Biliary atresia was the most common cause of end stage liver disease (35%). Mean age at follow up was 14 years (SD 5.48) and mean follow up was 8 years (SD 4.12 years). Eleven patients (48%) had poor bone health (osteopenia 22% and osteoporosis 26%). On univariate analysis, being on steroids at last follow up (odds ratio [OR] 13.2, 95% confidence interval [CI] 1.23-140.67, P = .03), weight at last follow up (OR 0.45, 95% CI 0.20-0.99, P = .04), platelets at last follow up (OR 0.98, 95% CI 0.96-s0.99, P = .02), hemoglobin at last follow up (OR 0.33, 95% CI 0.12-0.89, P = .03) were significantly associated with poor bone health. None of the variables were significant on multivariate analysis. At most recent follow up, 48% of patients demonstrated poor bone health by DEXA scans. More studies are required to evaluate predictors of poor bone health after LT in children.

Long-term glucocorticoids administration inhibits bone mineralization and has a negative impact on basic cellular mechanisms that are critical in the development and maintenance of bone strength. Steroids can cause osteoporosis in children and have a negative impact on bone mineral content (BMC) and bone mineral density (BMD). We aim to determine the BMD of children with idiopathic nephrotic syndrome (INS) who are on corticosteroids therapy. This cross-sectional study included 90 patients on corticosteroids therapy and 50 apparently healthy age and sex-matched children served as a control group. Renal functions, bone biochemistry, and parathyroid hormone (PTH) were measured in patients and controls. BMD was measured at the lumbar spinal region (L2-L4) using Dual-energy X-ray absorptiometry (DEXA) scan in both patients and controls groups. Serum PTH, phosphorous, and alkaline phosphatase levels were significantly higher in patients than in controls. There was a statistically significant reduction in blood calcium levels in patients compared to controls. Osteopenia was diagnosed by DEXA scan in 24 patients (26.7%) and osteoporosis in 12 patients (13.3 %). There was a statistically significant decline in BMD-z score, BMD, and BMC in patients compared to the healthy group. Patients with INS on corticosteroids treatment have a lower BMD than their peers. Pediatric INS patients had a high prevalence of osteopenia and osteoporosis as measured by DEXA. Steroid therapy has a deleterious impact on bone mineralization in children with INS.

PURPOSE: To assess vitamin D receptor (VDR) gene polymorphisms and bone mineral density and to investigate the possible risk factors of osteoporosis and fracture in rheumatoid arthritis (RA).

METHODS: A total of 97 RA patients and 45 matched controls were enrolled. Serum vitamin D level, VDR genotyping, dual-energy X-ray absorptiometry (DEXA) scan, trabecular bone score (TBS), and fracture risk assessment (FRAX) in 10 years were assessed. Disease activity score (DAS28) and modified health assessment questionnaire (MHAQ) were measured.

RESULTS: The mean age of the patients was 47.9 ± 8.9 years; 85 females, 12 males (F:M 7.1:1) and mean disease duration 9.4 ± 6.2 years. DAS28 was 4.52 ± 1.04 and MHAQ 0.6 ± 0.4. There was a significant difference between cases and controls as regards DEXA and FRAX (p < 0.0001) but the TBS and VDR genotyping were comparable (p = 0.29 and p = 0.12, respectively). The vitamin D level was comparable with the control (9.3 ± 6.5 vs 10.4 ± 7.5 ng/mL, p = 0.4). None of the patients was receiving anti-osteoporotic therapy or biologic therapy. There was a significant association between the presence of osteoporosis and age, disease duration, menopause, and rheumatoid factor (RF) positivity. The TBS was significantly lower and FRAX higher in patients with positive RF and anti-CCP. FRAX was significantly related and the TBS inversely with the age, disease duration, serum uric acid, alkaline phosphatase, and MHAQ.

CONCLUSIONS: Reduced BMD and increased tendency to fractures are remarkable in RA patients. Vitamin D level was decreased in patients and control, and VDR gene polymorphisms were not linked to RA. TBS and FRAX are effective tools to assess osteoporotic fractures in RA. Key Points • Reduced bone mineral density (BMD) and increased tendency to fractures are remarkable in rheumatoid arthritis (RA) patients. • Vitamin D level was decreased in patients and control, and VDR gene polymorphisms were not linked to RA. • Trabecular bone score (TBS) and fracture risk assessment (FRAX) in 10 years are effective tools to assess osteoporotic fractures in RA.

Advancements in shoot regeneration systems support biotechnology-based tools used in the genetic improvement of plant crops. This study aims to enhance shoot regeneration in potatoes by boosting polyamine content by adding AgNO3 to the shoot regeneration medium (MS medium supplemented with 30 g L−1 sucrose, 100 mg L−1 myoinositol, and 2.25 BA mg L−1). Five concentrations of AgNO3 (2, 4, 6, 8, and 10 mg L−1) were used in addition to a control. The effect of AgNO3 on regeneration assumed a more or less concentration-dependent bell-shaped curve peaking at 4 mg L−1. Enhancements in shoot regeneration were attributed to the known role of AgNO3 as an ethylene action blocker in addition to improvements in polyamine accumulation without an increase in H2O2 content, lipid peroxidation, or DNA damage. The uncoupling of shoot regeneration and polyamine content recorded at high AgNO3 concentrations can be attributed to the consumption of polyamines to counteract the synchronized oxidative stress manifested by increases in H2O2 content, lipid peroxidation, and DNA damage.